FMC FMC CORP
Chemicals & Allied Products · NYSE · SEC CIK 37785 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-22.0%
TTM net income YoY-696.3%
TTM EPS YoY-678.8%
Revenue 3-yr CAGR-17.2%
Net income 3-yr CAGR—
Margins
Gross margin22.0%
Operating margin-97.0%
Net margin-151.2%
FCF margin13.1%
EBITDA margin-91.0%
Returns
ROE-226.7%
ROA-42.6%
ROIC (approx.)-38.4%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets99.9%
Debt / equity—
Current ratio1.66x
Interest coverage-9.96x
Cash quality & payout
Operating cash flow / net income-0.10x
Accruals ratio-46.8%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.47B | $4.25B |
| Cost of revenue | $2.18B | $2.60B |
| Gross profit | $1.28B | $1.65B |
| R&D expense | $266.10M | $278.00M |
| SG&A expense | $684.90M | $644.60M |
| Operating income | -$1.63B | $506.50M |
| Interest expense | $239.60M | $235.80M |
| Pretax income | -$1.89B | $252.50M |
| Income tax | $314.20M | -$150.90M |
| Net income | -$2.24B | $341.10M |
| EBITDA | -$1.45B | $682.80M |
| EPS (basic) | -17.88 | 2.73 |
| EPS (diluted) | -17.88 | 2.72 |
| Dividends declared per share | 1.82 | 2.32 |
| Weighted avg. shares (diluted) | 125.16M | 125.36M |
| Balance sheet | ||
| Cash & equivalents | $584.50M | $357.30M |
| Receivables | $2.06B | $2.90B |
| Inventory | $1.22B | $1.20B |
| Current assets | $4.96B | $4.96B |
| PP&E, net | $707.40M | $849.70M |
| Goodwill | $0 | $1.51B |
| Intangibles | $2.36B | $2.36B |
| Total assets | $9.69B | $11.65B |
| Current liabilities | $3.76B | $3.02B |
| Short-term debt | $1.31B | $337.40M |
| Long-term debt | $2.77B | $3.03B |
| Total debt | $4.07B | $3.37B |
| Total liabilities | $7.59B | $7.14B |
| Shareholders' equity | $2.07B | $4.49B |
| Net debt | $3.49B | $3.01B |
| Cash flow statement | ||
| Operating cash flow | -$6.20M | $736.70M |
| Capital expenditure | $96.30M | $67.90M |
| Free cash flow | -$102.50M | $668.80M |
| Investing cash flow | -$99.70M | $263.60M |
| Financing cash flow | $386.00M | -$870.10M |
| Depreciation & amortization | $173.60M | $176.30M |
| Stock-based compensation | $24.00M | $23.80M |
| Dividends paid | $291.30M | $290.60M |
| Share buybacks | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.